How Much Did LifeVantage (NASDAQ:LFVN) Revenue Fall in Its First Fiscal Quarter of 2027?

Sonal Goyal

10 November 2026 06:56 PM AEDT

How Much Did LifeVantage (NASDAQ:LFVN) Revenue Fall in Its First Fiscal Quarter of 2027?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue was $37.1 million for the fiscal first quarter of 2027, a decrease of 22.0%.
Revenue in the Americas decreased 22.2% from the prior-year period.
Adjusted EBITDA was $1.9 million for the quarter.
The prior-year quarter reported Revenue of $47.6 million.

LifeVantage Corporation (NASDAQ:LFVN) reported revenue of $37.1 million for its fiscal first quarter of 2027, which ended September 30, 2026. The figure was a decrease of 22.0% from the revenue of $47.6 million reported in the same quarter a year earlier. The company describes itself as a health and wellness company with products designed to activate health processes at the cellular level. Adjusted EBITDA for the quarter was $1.9 million.

Revenue by Region

Revenue in the Americas decreased 22.2% from the prior-year quarter. The company also reported a decline in its Asia Pacific revenue during the period. The company's results are reported on a fiscal calendar, so the first quarter of fiscal 2027 covers July through September 2026.

The company's revenue of $37.1 million compares with $47.6 million in the prior-year quarter.

Adjusted EBITDA

Adjusted EBITDA was $1.9 million in the quarter. The prior-year quarter's adjusted EBITDA was higher. Adjusted EBITDA is a non-GAAP measure that the company uses to exclude certain items from its operating results. The company's reconciliation of adjusted EBITDA to Net Income is included in its full financial statements.

The company's cost structure is shaped by its distributor network and its product marketing, and the figures for the quarter show revenue and adjusted EBITDA both lower than in the prior-year period.

Product and Company Background

LifeVantage's products are described by the company as designed to activate health processes at the cellular level, and its reported regions include the Americas and Asia Pacific.

The company's latest quarter is the first reported for fiscal 2027. The results are the first disclosed for the year, and the comparison base is the first quarter of fiscal 2026.

Final Word

LifeVantage reported fiscal first-quarter 2027 revenue of $37.1 million, down 22.0% from $47.6 million a year earlier, with Americas revenue down 22.2%. Adjusted EBITDA for the quarter was $1.9 million.

FAQs

Q: What was LifeVantage's revenue in the fiscal first quarter of 2027?

A: Revenue was $37.1 million, a decrease of 22.0% from the prior-year quarter.

Q: How much did Americas revenue change?

A: Revenue in the Americas decreased 22.2% from the prior-year period.

Q: What was adjusted EBITDA for the quarter?

A: Adjusted EBITDA was $1.9 million for the quarter ended September 30, 2026.

Q: What was the prior-year quarter's revenue?

A: The company reported revenue of $47.6 million in the quarter ended September 30, 2025.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.